Tech Company Financing Transactions
Immatics Funding Round
Immatics, based in Tuebingen, scored $35 million from Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
7/24/2023
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Undisclosed
Investors
Bristol Myers Squibb (Lead Investor)
Proceeds Purpose
This investment is further testimony to the strength of the relationship and of our differentiated platform technologies that are the foundation of our TCR-based cell therapies and bispecifics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Paul-Ehrlich-Strasse 15
Tuebingen, 72076
DE
Tuebingen, 72076
DE
Phone
Undisclosed
Website
Email Address
Overview
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Harpreet Singh
Chief Financial Officer
Arnd Christ
Chief Operating Officer
Steffen Walter
Co-Founder
Toni Weinschenk
Browse more venture capital transactions:
Prev: 7/24/2023: BizAway venture capital transaction
Next: 7/24/2023: Voltpost venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs